Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01383954 · ClinicalTrials.gov registry record · Phase 4

The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis

A Phase 4 study of Knee Osteoarthritis, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 4
Development phase
52
Enrollment target
1
Study location

NCT01383954 is a Phase 4 study of Knee Osteoarthritis that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 52 participants, below the 304-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01383954, a Phase 4 study of Knee Osteoarthritis, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 4
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

The purpose of this proposed study is to conduct a trial with knee osteoarthritis (OA) patients using the diclofenac gel.

Conditions Studied

Interventions

  • DRUG Diclofenac Gel

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Chestnut Hill

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2011-06
Est. Completion 2012-12
Phase Phase 4

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT01383954

The ClinicalTrials.gov registry entry for NCT01383954 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (83% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Knee Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which Diclofenac Gel is the first listed.

NCT01383954 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01383954 about?

NCT01383954 is a clinical study titled "The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis". The purpose of this proposed study is to conduct a trial with knee osteoarthritis (OA) patients using the diclofenac gel.

What is the current status of trial NCT01383954?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2011-06. Estimated completion is 2012-12.

What conditions does trial NCT01383954 study?

This clinical trial studies the following conditions: Knee Osteoarthritis.

What interventions are being tested in trial NCT01383954?

The interventions under investigation include: Diclofenac Gel (DRUG).

Who is sponsoring clinical trial NCT01383954?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01383954 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Knee Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.